Singapore markets close in 1 hour 31 minutes

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
36.09+0.65 (+1.83%)
At close: 04:00PM EST
36.09 0.00 (0.00%)
After hours: 05:32PM EST
Full screen
Trade prices are not sourced from all markets
Previous close35.44
Open35.93
Bid0.00 x 800
Ask0.00 x 1200
Day's range35.45 - 36.47
52-week range30.12 - 58.35
Volume276,763
Avg. volume195,690
Market cap2.111B
Beta (5Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-0.07
Earnings date21 Feb 2022 - 25 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est54.64
  • Business Wire

    Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

    MONROVIA, Calif., HONG KONG & BOSTON, November 21, 2021--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma ("Zenas"), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based therapies, today announced that Zenas has acquired from Xencor exclusive worldwide rights to develop, manufac

  • Business Wire

    Xencor to Present at Upcoming Investor Conferences

    MONROVIA, Calif., November 19, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:

  • Business Wire

    Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting

    MONROVIA, Calif., November 12, 2021--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program, XmAb662, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).